Hospital
Mountain Vista Medical Center LP
Mountain Vista Medical Center LP was paid $20.74M by Medicaid between Jan 2018 and Oct 2024, across 240 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoMOUNTAIN VISTA MEDICAL CENTER LP
MESA, AZ 85209
MESA, AZ 85209
33aNPI1235212721assigned 10/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.74M
24GClaims609,530
24DCodes billed240
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#26 of 78
Median peer was paid$12.21M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,515 | $3.27M | |
| 2019 | 91,226 | $3.05M | |
| 2020 | 84,839 | $2.79M | |
| 2021 | 107,169 | $3.60M | |
| 2022 | 105,039 | $3.68M | |
| 2023 | 78,560 | $2.88M | |
| 2024incomplete | 45,182 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 16,263 | 14,287 | $3.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 3,781 | 3,496 | $2.35M |
| 80053 | Comprehensive metabolic panel | 9.4% | 27,490 | 21,718 | $1.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 12,535 | 11,767 | $1.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.0% | 16,293 | 14,961 | $1.44M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.0% | 2,853 | 2,605 | $1.25M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.8% | 2,952 | 2,806 | $1.20M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 4.3% | 1,231 | 1,094 | $892K |
| 93458 | 3.4% | 751 | 685 | $699K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 5,440 | 2,070 | $542K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.5% | 1,143 | 1,077 | $524K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.0% | 842 | 803 | $418K |
228 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 2.0% | 1,541 | $414K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 7,590 | $403K |
| C1776 | Joint device (implantable) | 1.6% | 402 | $332K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,024 | $200K |
| 43235 | <1% | 714 | $194K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,755 | $174K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,635 | $167K |
| 59025 | Fetal non-stress test | <1% | 1,765 | $159K |
| 11045 | <1% | 339 | $158K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 508 | $141K |
| 27447 | <1% | 18 | $129K | |
| 93975 | <1% | 303 | $111K | |
| 73562 | <1% | 840 | $104K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,336 | $92K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 223 | $88K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 307 | $86K |
| 80050 | General health panel | <1% | 633 | $83K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,373 | $82K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 13 | $76K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,543 | $46K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 866 | $46K |
| 58571 | <1% | 12 | $44K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 702 | $43K |
| G0378 | Hospital observation service, per hour | <1% | 9,543 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,663 | $36K |
| 47563 | <1% | 13 | $35K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,282 | $34K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 505 | $25K |
| 73630 | <1% | 387 | $23K | |
| 70486 | <1% | 108 | $21K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 573 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,328 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,381 | $20K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,030 | $18K |
| 73030 | <1% | 588 | $17K | |
| 73610 | <1% | 208 | $17K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 152 | $16K |
| 73130 | <1% | 216 | $15K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 52 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,839 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 755 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,522 | $11K |
| 93976 | <1% | 255 | $11K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 189 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 106 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 929 | $9K |
| 88304 | <1% | 1,261 | $8K | |
| 72100 | <1% | 153 | $8K | |
| C1781 | Mesh (implantable) | <1% | 109 | $8K |
| 96376 | <1% | 2,491 | $8K | |
| 87186 | <1% | 2,241 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,445 | $7K |
| 72131 | <1% | 29 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 44 | $7K |
| 73110 | <1% | 28 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,779 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,248 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,442 | $5K |
| 93971 | <1% | 815 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 56 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 47 | $5K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 312 | $4K |
| 73560 | <1% | 240 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| A4649 | Surgical supply; miscellaneous | <1% | 544 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 336 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 217 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,383 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,071 | $3K |
| 86900 | <1% | 2,833 | $3K | |
| 71250 | <1% | 13 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,396 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,094 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,517 | $2K |
| 87428 | <1% | 1,849 | $2K | |
| 87088 | <1% | 2,696 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,966 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 12 | $1K |
| 84484 | <1% | 9,977 | $1K | |
| 84703 | <1% | 5,334 | $1K | |
| 81001 | <1% | 10,411 | $1K | |
| 94761 | <1% | 529 | $929.12 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,549 | $789.76 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 80 | $724.17 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,296 | $711.13 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16 | $588.39 |
| 74018 | <1% | 405 | $565.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,295 | $488.21 |
| 83690 | <1% | 6,723 | $448.99 | |
| 81025 | <1% | 4,574 | $418.92 | |
| 87400 | <1% | 973 | $414.30 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,128 | $401.56 |
| 83605 | <1% | 4,504 | $399.49 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,506 | $399.07 |
| 85379 | <1% | 1,522 | $391.62 | |
| 83880 | <1% | 2,190 | $386.22 | |
| 82962 | <1% | 8,143 | $374.14 | |
| 73502 | <1% | 53 | $358.26 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $335.73 |
| A9270 | Non-covered item or service | <1% | 9,799 | $290.79 |
| 85610 | <1% | 8,549 | $290.36 | |
| 97597 | <1% | 23 | $275.60 | |
| 85027 | <1% | 3,918 | $265.32 | |
| 84702 | <1% | 1,381 | $257.99 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 38 | $256.30 |
| 81003 | <1% | 8,273 | $252.67 | |
| 83735 | <1% | 4,656 | $245.49 | |
| 90715 | <1% | 600 | $243.20 | |
| 85730 | <1% | 4,628 | $208.23 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,996 | $207.12 |
| 97162 | <1% | 788 | $193.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,507 | $123.93 |
| 87040 | <1% | 2,645 | $122.19 | |
| 80061 | Lipid panel | <1% | 385 | $121.46 |
| 82550 | <1% | 1,775 | $115.14 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,609 | $110.11 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,342 | $107.02 |
| 88342 | <1% | 705 | $94.08 | |
| 87081 | <1% | 665 | $91.71 | |
| J3490 | Unclassified drugs | <1% | 431 | $89.53 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,225 | $86.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 671 | $85.07 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,964 | $84.65 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,101 | $84.26 |
| 97165 | <1% | 690 | $80.54 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,862 | $75.41 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,961 | $73.84 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,055 | $73.77 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,024 | $65.43 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,517 | $63.10 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,199 | $60.95 |
| 82947 | <1% | 838 | $52.56 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,567 | $50.88 |
| 73090 | <1% | 19 | $50.60 | |
| 76801 | <1% | 202 | $46.38 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,133 | $43.11 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56 | $42.99 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $42.99 |
| 87070 | <1% | 540 | $41.17 | |
| 80047 | <1% | 1,563 | $41.04 | |
| 94760 | <1% | 773 | $40.51 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,122 | $34.48 |
| 87077 | <1% | 1,276 | $28.31 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 515 | $27.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,928 | $26.86 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 756 | $25.00 |
| 86901 | <1% | 2,834 | $22.64 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 853 | $22.30 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 506 | $21.54 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,406 | $20.10 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 622 | $17.70 |
| 86850 | <1% | 2,584 | $15.16 | |
| 82077 | <1% | 349 | $13.82 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,334 | $13.14 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,994 | $9.54 |
| 87205 | <1% | 642 | $9.43 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,694 | $9.19 |
| 97116 | <1% | 715 | $7.21 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 550 | $7.06 |
| 80076 | <1% | 165 | $6.54 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 491 | $5.18 |
| 87420 | <1% | 125 | $4.68 | |
| 84100 | <1% | 287 | $4.21 | |
| 87147 | <1% | 277 | $3.91 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 228 | $0.80 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,949 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 239 | $0.00 |
| A6255 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 62 | $0.00 |
| 85347 | 0% | 279 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 631 | $0.00 |
| 97161 | 0% | 1,131 | $0.00 | |
| 99152 | 0% | 1,747 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 167 | $0.00 |
| 84439 | 0% | 98 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 295 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 376 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 1,126 | $0.00 |
| 85007 | 0% | 214 | $0.00 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 226 | $0.00 |
| 80143 | 0% | 316 | $0.00 | |
| 80179 | 0% | 281 | $0.00 | |
| 29125 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 48 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 224 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 15 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 87 | $0.00 |
| 96367 | 0% | 19 | $0.00 | |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 56 | $0.00 |
| 87075 | 0% | 16 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 49 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 184 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 166 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 20 | $0.00 |
| 84600 | 0% | 13 | $0.00 | |
| 83540 | 0% | 12 | $0.00 | |
| 82948 | 0% | 24 | $0.00 | |
| C1769 | Guide wire | 0% | 1,937 | $0.00 |
| 72170 | 0% | 29 | $0.00 | |
| 86140 | 0% | 164 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 1,758 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,600 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,188 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 35 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 454 | $0.00 |
| 97035 | 0% | 441 | $0.00 | |
| 80329 | 0% | 664 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 131 | $0.00 |
| 80320 | 0% | 1,481 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 139 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 33 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 94 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 284 | $0.00 |
| 88307 | 0% | 172 | $0.00 | |
| A4215 | Needle, sterile, any size, each | 0% | 395 | $0.00 |
| 87807 | 0% | 161 | $0.00 | |
| 84132 | 0% | 44 | $0.00 | |
| 76830 | Ultrasound, transvaginal | 0% | 96 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 306 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 79 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 19 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 34 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 24 | $0.00 |
| 36416 | 0% | 31 | $0.00 | |
| 82553 | 0% | 45 | $0.00 | |
| 97166 | 0% | 31 | $0.00 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 13 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOLICH, JACOB (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Mountain Vista Medical Center, LP | Florence, AZ | $8.21M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.